CareDx Inc
Gesloten
SectorGezondheidszorg
49.95 -0.16
Overzicht
Wijziging aandelenprijs
24u
Min
49.52
Max
50.58
Inkomsten | 108M 111M |
|---|---|
Verkoop | 14M 132M |
K/W Sectorgemiddelde | 24.462 56.597 |
EPS | 0.17 |
Winstmarge | 83.848 |
Werknemers | 761 |
EBITDA | -3.8M 4.3M |
Volgende Winsten | 3 nov 2026 |
|---|
Marktkapitalisatie | 754M 2.6B |
|---|---|
Vorige openingsprijs | 50.11 |
Vorige sluitingsprijs | 49.95 |
Nieuwssentiment
By Acuity
50%
50%
146 / 339 Rangschikking in Healthcare
CareDx Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
CareDx Inc Prognose
Sentiment
By Acuity
146 / 339 Rangschikking in Gezondheidszorg
Nieuwssentiment
Neutral
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over CareDx Inc
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
